
---
title: '呼吸道合胞病毒疫苗和单抗最新研究进展（13）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956680'
author: 科学网
comments: false
date: Sun, 04 Sep 2022 13:43:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956680'
---

<div>   
<p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;padding:0 0 0 0 "><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 36px;background: #FFFFFF">呼吸道合胞病毒预防制剂曙光在前</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 36px;background: #FFFFFF">:　</span></strong><br></p><p style="margin-top:45px;margin-right:0;margin-bottom:69px;margin-left:0;padding:0 0 0 0 "><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 36px;background: #FFFFFF"><span style="font-family:Shaker2Lancet-Bold">疫苗和单克隆抗体百舸争流</span></span></strong></p><p style="margin-top:45px;margin-right:0;margin-bottom:69px;margin-left:0;padding:0 0 0 0 "><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">前言：</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">　　新冠病毒大流行的将近３年，也是世界疫苗行业突飞猛进、疫苗研发技术日新月异、硕果累累的３年。疫苗制备的多种技术途径都得到深度开发，若干种新兴的技术途径如</span><span style="font-family:Microsoft YaHei UI">mRNA疫苗获得了空前的成功，在世界各地大行其道，在多种传染病以及癌症和其他慢性病的防治领域都在不断开花结果。</span></span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><strong>　　</strong><strong>　　</strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">呼吸道合胞病毒（</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 24px">Respiratory syncytial virus，</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 24px"><span style="font-family:Shaker2Lancet-Bold">）</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">是一种历史悠久、危害极大的传染病，其疫苗的研发已经有四十年的历史，</span><span style="font-family:Microsoft YaHei UI"> 但最初开发的疫苗反而会引发</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">疫苗相关性呼吸道疾病（</span><span style="font-family:Microsoft YaHei UI">VAERD，Vaccine-associated enhanced respiratory diseases</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px">）</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">，即未接触过</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的儿童在接种了疫苗后，如果再接触到该病毒反而会发生更严重的</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">疾病。诸如此类的问题导致针对</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的疫苗一直未能上市。乘新冠病毒疫苗大跃进的东风，已赚得盆满钵满的疫苗巨头如</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">辉瑞（</span><span style="font-family:Microsoft YaHei UI">Pfizer)</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">、</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">莫德纳（</span><span style="font-family:Microsoft YaHei UI">Moderna</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">）和</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">葛兰素史克</span><span style="font-family:Microsoft YaHei UI">(GSK)</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">等目前都在</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的疫苗开发上快马加鞭，有望在较短时间内取得重大突破。</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><strong>　　</strong><strong>　　</strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">疫苗和单克隆抗体研究领域来自世界各地的顶级研究人员（约５０人）近期联名在国际著名专业杂志《</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #FF0000;letter-spacing: 0;font-size: 24px">Lancet</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"> Infect Dis》上发表综述论文，介绍相关最新研究进展（见</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #222222;letter-spacing: 0;font-size: 24px">参考文献</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">），本博客将分数次介绍此综述的主要内容。</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 24px">目录：</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px">摘要</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">一</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px">前言</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">二</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px">方法</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">三</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">教训（</span>Lessons learned）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">四</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">减毒活疫苗（</span>live attenuated vaccines，LAVs ）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">五</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">嵌合疫苗（</span>Chimeric ）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">六</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">亚单位疫苗（</span>Subunit）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">七</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">基于颗粒的疫苗（</span>Particle-based ）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">八</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">核酸疫苗（</span>Nucleic acid）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">九</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">重组载体疫苗（</span>Recombinant vectors）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">十</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">单克隆抗体（</span>MAbs）</span></strong></p><p style="margin: 0 0 24px;text-indent: 0;padding: 0;background: rgb(255, 255, 255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">十一</span>.　讨论　</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #006F3C;letter-spacing: 0;font-size: 29px"><span style="font-family:Shaker2Lancet-Bold">十</span>.　单克隆抗体（MAbs）</span></strong></p><p style="margin: 15px 0px 39px; text-indent: 0px; padding: 0px; background: rgb(255, 255, 255); line-height: 2em;"><strong>　　</strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">单克</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">隆抗体（</span>MAbs）</span></span></strong><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">因其对病原体的高度特异性而被称为对抗感染的灵丹妙药</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">或</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">魔弹（</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px">magic bullet</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">）</span></span></span></strong><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">。</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">对于</span>RSV，随着对RSV</span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">融合</span></span></span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">（Ｆ，</span></span></span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px">fusion</span></span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">）</span></span></span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">蛋白</span></span></span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">结构和免疫原性认识的增加，针对</span>RSV</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"> pre-F蛋白</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">（</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">前</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">融合蛋白）</span></span></span></strong><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">上高度中和敏感表位的下一代抗体应运而生。此外，下一代</span>RSV抗体已被设计为</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">包含</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">Fc突变</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">片段</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">，以延长半衰期，并使所有婴儿在整个</span>RSV季节内</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">避免</span><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px">下呼吸道疾病。</span></p><p style="text-indent: 0px; margin: 15px 0px 39px; padding: 0px; background: rgb(255, 255, 255); line-height: 2em;"><span style="text-indent: 43px; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">        主要的候选单抗药物是</span><span style="font-size: 24px; color: #0070C0;"><strong style="text-indent: 43px;"><span style="font-size: 24px; font-family: ScalaLancetPro; line-height: 200%;">nirsevimab</span></strong></span><span style="text-indent: 43px; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">(以前称为med -8897)，这是一种针对F蛋白位点Ø的人源单抗，Fc部分有YTE突变，可以延长半衰期。2期临床试验的结果(n=1453)显示，<strong style="color: rgb(0, 112, 192); font-size: 24px; white-space: normal; background-color: rgb(255, 255, 255); text-indent: 43px;"><span style="font-family: ScalaLancetPro; line-height: 48px;">nirsevimab</span></strong>对接受医疗护理的RSV LRTI（下呼吸道感染）的疗效为70% (95% CI 52 - 81)，对因RSV住院治疗的早产儿的疗效为78%(95% CI 52 ~ 90)，与3期临床试验的中期结果相似:在健康的晚期早产儿和足月婴儿(n=1490)中，对RSV引起的下呼吸道感染的疗效是75%(50 ~ 87)，与对RSV导致的住院的疗效是62%(-9 ~ 87)。<strong style="color: rgb(0, 112, 192); font-size: 24px; white-space: normal; background-color: rgb(255, 255, 255); text-indent: 43px;"><span style="font-family: ScalaLancetPro; line-height: 48px;">nirsevimab</span></strong>的安全性与目前在有先天性心脏或肺部疾病的婴儿(n=310）和妊娠29周至35周的早产儿(n=615)中每月使用一次的标准的palivizumab治疗的安全性相似。发现有针对RSV单克隆抗体的耐药突变毒株产生，但对整个病毒复制无影响，在流行毒株中具有较低的自然发生频率。与已批准的palivizumab相比，<strong style="color: rgb(0, 112, 192); font-size: 24px; white-space: normal; background-color: rgb(255, 255, 255); text-indent: 43px;"><span style="font-family: ScalaLancetPro; line-height: 48px;">nirsevimab</span></strong>最突出的优势是，与必须每月注射相比，一次肌肉注射就可以使婴儿在整个流行季节得到保护，从而降低了成本(预计会有类似疫苗的定价)，因而不仅可用于高危儿童，还可用于所有婴儿。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro; line-height: 200%; font-size: 24px; color: #0070C0;">Clesrovimab</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"> (MK-1654)是一种半衰期延长的单克隆抗体，与<strong style="font-family: ScalaLancetPro; text-indent: 43px; white-space: normal; color: rgb(0, 112, 192); font-size: 24px; background-color: rgb(255, 255, 255);"><span style="line-height: 48px;">nirsevimab</span></strong>具有相同的YTE突变，靶点为位点IV(由于部分地<span style="font-family:ScalaLancetPro">靶向</span>RSV F蛋白的V位点，因而<span style="font-family:ScalaLancetPro">会优先结合</span>pre-F)。该单抗正在进行婴儿2b/3期临床<span style="font-family:ScalaLancetPro">试验</span>(NCT04767373)和3期临床<span style="font-family:ScalaLancetPro">试验</span>(NCT04938830)。该单抗在体外对RSV临床分离株表现出高效性，对RSV A亚群和B亚群也同样有效。<span style="font-family:ScalaLancetPro">人类攻毒试验</span> (n=80)显示病毒攻毒后病毒载量减少，RSV有症状的<span style="font-family:ScalaLancetPro">感染率降低。</span> <span style="font-family:ScalaLancetPro">对血清中和抗体和临床终点之间的关系进行了</span></span><strong><span style="text-decoration: underline; line-height: 200%; color: #2A2B2E; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: "Segoe UI";">荟萃分析</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">（</span></strong><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;"> meta-analysis</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">）</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">;该项<span style="font-family:ScalaLancetPro">研究估计，单次</span>75毫克的剂量对足月婴儿的疗效将超过75%，持续5个月。开发该制剂的公司致力于通过持续的研究和创新来帮助解决不确定性和改善获取问题，以帮助解决有预防潜力的儿童疾病负担问题。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">可负担性</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">（Affordability）</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">仍然是单抗开发的一个需要考虑的关键因素，因为它是</span><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">全球</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">可</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">获取</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">（</span></strong><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">global access</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">）</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">的一个潜在障碍。目前有三种不同的临床开发努力来规避这个问题</span>:(1)一种负担得起的半衰期延长的针对位点Ø的单抗<span style="font-family:ScalaLancetPro">，</span>(2)局部给药<span style="font-family:ScalaLancetPro">，</span>(3)采用<span style="font-family:ScalaLancetPro">生物仿制药。首先，旨在用于中低收入国家的</span><span style="font-family: ScalaLancetPro; line-height: 200%; font-size: 24px; color: #00B0F0;"><strong>RSM01</strong></span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">，一种针对位点Ø的单抗的一期临床<span style="font-family:ScalaLancetPro">试验的目标价格低于</span>5美元/剂。第二，通过滴鼻剂局部无针给药的单抗<span style="font-family: ScalaLancetPro; line-height: 200%; font-size: 24px; color: #00B0F0;"><strong>palivizumab</strong></span>，是一种已获市场批准的针对<span style="font-family:ScalaLancetPro">位点</span>II的<span style="font-family:ScalaLancetPro">单抗，可以通过减少所需的药物剂量来显著降低成本。鼻内使用</span><strong style="color: rgb(0, 176, 240); font-family: ScalaLancetPro; font-size: 24px; text-indent: 43px; white-space: normal;">palivizumab</strong>预防RSV感染的1期和2b期临床<span style="font-family:ScalaLancetPro">试验结果将很快公布。最后，</span><strong style="color: rgb(0, 176, 240); font-family: ScalaLancetPro; font-size: 24px; text-indent: 43px; white-space: normal;">palivizumab</strong>的生物仿制药正在与荷兰</span><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;"><span style="font-family:ScalaLancetPro">乌得勒支平价生物治疗中心</span>(Utrecht Center for Affordable biotheraptics</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)建立公私合作关系，开发一种<strong style="color: rgb(0, 176, 240); font-family: ScalaLancetPro; font-size: 24px; text-indent: 43px; white-space: normal;">palivizumab</strong>生物仿制药，该中心于2020年完成了人类挑战试验(n=56)，但该试验的结果尚未公开。开发下一代单克隆抗体的需要重点考虑的因素是</span><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">可负担性</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">（</span></strong><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">affordability</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">）</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">，这可以通过投资于更高效率的生产或开发生物仿制药或潜在地通过局部给药来实现。同样，需要监测病毒耐药性，并有<span style="font-family:ScalaLancetPro">可能通过使用针对多个表位的单抗鸡尾酒来预防。在大多数中低收入国家，每月使用鼻内单抗或</span><strong style="color: rgb(0, 176, 240); font-family: ScalaLancetPro; font-size: 24px; text-indent: 43px; white-space: normal;">palivizumab</strong>生物仿制药可能存在整体规划方面的限制。由于病毒会对单抗产生耐药性而导致单抗失去疗效，针对不同抗原表位的单抗组合可能为解决这个问题提供一种可能的方案。然而，这种解决方案存在实际障碍，因为该单抗组合必须由单独注册的单抗组成。不过值得庆幸的是，到目前为止，正在开发的单抗的表位高度保守，而自然产生的针对抗体的耐药毒株极为罕见，在体外与非耐药病毒株相比显示出类似或更低的病毒适应度。</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">（未完待续）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 24px">参考文献：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 20px">Natalie I Mazur,</span></em><em>　</em><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 20px">et al., </span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px">Respiratory syncytial virus prevention within reach:</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px"> the vaccine and monoclonal antibody landscape, </span></strong><em><span style="font-family: Shaker2Lancet-Bold;color: #FF0000;letter-spacing: 0;font-size: 20px">Lancet Infect Dis</span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px"><span style="font-family:Shaker2Lancet-Bold">，</span> Published online August 8, 2022， </span></strong><span style="font-family: Tahoma;color: #505050;letter-spacing: 0;font-size: 20px">DOI: </span><a href="https://doi.org/10.1016/S1473-3099(22)00291-2" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px">https://doi.org/10.1016/S1473-3099(22)00291-2</span></a><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 20px">，</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;color: #6666CC;letter-spacing: 0;font-size: 20px">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext</span></span></a><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px">.</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 24px">相关博文：</span></strong><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank"></a></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956680" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（１）</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px"> 2022-08-12</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350986" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956679" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>2）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-13</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351276" target="_blank"></a><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956678" title alt="image.png" referrerpolicy="no-referrer"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351276" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>3）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-15</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351490" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>4）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-17</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351871" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>5）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-20</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352158" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>6）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-22</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352448" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956677" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>7）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-24</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352713" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956676" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>8）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-26</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956675" title alt="image.png" referrerpolicy="no-referrer"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352981" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>9）</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-28</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1353081" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956674" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>10）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-29</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1353361" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956673" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>11）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-31</span></p><p style="line-height: 200%;"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1353798" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956672" title alt="image.png" referrerpolicy="no-referrer"><strong><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>12）</span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2022-09-03</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-347754-1353965.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-347754-1353965.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1353798.html" target="_black">呼吸道合胞病毒疫苗和单抗最新研究进展（12）</a><br>                    <!--大赛结束-->
                                        
  
</div>
            